Archean Chemical Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:42 pm

Quick Insight

Archean Chemical Industries Ltd stands as a robust player in the inorganic chemicals industry with a current share price of 655 and a market capitalization of 8,088 Cr. The company's P/E ratio of 36.6 signifies a premium valuation, supported by a healthy ROE of 12.0% and ROCE of 16.0%. With a solid operating profit margin of 30% and a net profit of 185 Cr, Archean Chemical Industries Ltd showcases operational efficiency. Furthermore, the company's comfortable ICR of 43.37x and a P/BV ratio of 3.41x indicate a strong financial position. Despite the absence of prominent institutional investors, the company's robust reserves of 1,855 Cr and manageable borrowings of ₹108 Cr underpin its stability and growth potential in the sector.

Competitors of Archean Chemical Industries Ltd

All Competitor Stocks of Archean Chemical Industries Ltd

Quarterly Result

Last Updated: August 1, 2025, 7:30 am

Below is a detailed analysis of the quarterly data for Archean Chemical Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 279.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Mar 2025) to 279.00 Cr., marking a decrease of 43.00 Cr..
• For Expenses, as of Jun 2025, the value is 196.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 232.00 Cr. (Mar 2025) to 196.00 Cr., marking a decrease of 36.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 7.00 Cr..
• For OPM %, as of Jun 2025, the value is 30.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Mar 2025) to 30.00%, marking an increase of 2.00%.
• For Other Income, as of Jun 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 8.00 Cr..
• For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 28.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 6.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 4.20. The value appears to be declining and may need further review. It has decreased from 4.72 (Mar 2025) to 4.20, marking a decrease of 0.52.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:56 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:51 pm

Below is a detailed analysis of the balance sheet data for Archean Chemical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,682.00 Cr. (Mar 2024) to 1,855.00 Cr., marking an increase of 173.00 Cr..
• For Borrowings, as of Mar 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 39.00 Cr. (Mar 2024) to 108.00 Cr., marking an increase of 69.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 261.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 246.00 Cr. (Mar 2024) to 261.00 Cr., marking an increase of 15.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,249.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,991.00 Cr. (Mar 2024) to 2,249.00 Cr., marking an increase of 258.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,071.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,086.00 Cr. (Mar 2024) to 1,071.00 Cr., marking a decrease of 15.00 Cr..
• For CWIP, as of Mar 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 28.00 Cr., marking an increase of 7.00 Cr..
• For Investments, as of Mar 2025, the value is 350.00 Cr.. The value appears strong and on an upward trend. It has increased from 347.00 Cr. (Mar 2024) to 350.00 Cr., marking an increase of 3.00 Cr..
• For Other Assets, as of Mar 2025, the value is 800.00 Cr.. The value appears strong and on an upward trend. It has increased from 537.00 Cr. (Mar 2024) to 800.00 Cr., marking an increase of 263.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,249.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,991.00 Cr. (Mar 2024) to 2,249.00 Cr., marking an increase of 258.00 Cr..

Notably, the Reserves (1,855.00 Cr.) exceed the Borrowings (108.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Archean Chemical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 25.90 (Mar 24) to 13.13, marking a decrease of 12.77.
• For Diluted EPS (Rs.), as of Mar 25, the value is 13.12. This value is within the healthy range. It has decreased from 25.87 (Mar 24) to 13.12, marking a decrease of 12.75.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.57. This value is within the healthy range. It has decreased from 31.55 (Mar 24) to 19.57, marking a decrease of 11.98.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 84.34. It has decreased from 107.79 (Mar 24) to 84.34, marking a decrease of 23.45.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 28.47. This value is within the healthy range. It has decreased from 41.00 (Mar 24) to 28.47, marking a decrease of 12.53.
• For PBIT / Share (Rs.), as of Mar 25, the value is 22.04. This value is within the healthy range. It has decreased from 35.30 (Mar 24) to 22.04, marking a decrease of 13.26.
• For PBT / Share (Rs.), as of Mar 25, the value is 18.13. This value is within the healthy range. It has decreased from 34.62 (Mar 24) to 18.13, marking a decrease of 16.49.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
• For PBDIT Margin (%), as of Mar 25, the value is 33.75. This value is within the healthy range. It has decreased from 38.04 (Mar 24) to 33.75, marking a decrease of 4.29.
• For PBIT Margin (%), as of Mar 25, the value is 26.13. This value exceeds the healthy maximum of 20. It has decreased from 32.75 (Mar 24) to 26.13, marking a decrease of 6.62.
• For PBT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has decreased from 32.11 (Mar 24) to 21.49, marking a decrease of 10.62.
• For Net Profit Margin (%), as of Mar 25, the value is 15.57. This value exceeds the healthy maximum of 10. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.57. This value is within the healthy range. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.69. This value is below the healthy minimum of 15. It has decreased from 18.74 (Mar 24) to 8.69, marking a decrease of 10.05.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.38. This value is within the healthy range. It has decreased from 22.67 (Mar 24) to 12.38, marking a decrease of 10.29.
• For Return On Assets (%), as of Mar 25, the value is 6.77. This value is within the healthy range. It has decreased from 15.51 (Mar 24) to 6.77, marking a decrease of 8.74.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.09, marking an increase of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has decreased from 0.69 (Mar 24) to 0.46, marking a decrease of 0.23.
• For Current Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.38 (Mar 24) to 3.50, marking a decrease of 1.88.
• For Quick Ratio (X), as of Mar 25, the value is 2.65. This value exceeds the healthy maximum of 2. It has decreased from 4.44 (Mar 24) to 2.65, marking a decrease of 1.79.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 4. It has increased from 0.32 (Mar 24) to 0.42, marking an increase of 0.10.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 17.37 (Mar 24) to 0.00, marking a decrease of 17.37.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.23 (Mar 24) to 0.00, marking a decrease of 14.23.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 82.63 (Mar 24) to 0.00, marking a decrease of 82.63.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 85.77 (Mar 24) to 0.00, marking a decrease of 85.77.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 43.37. This value is within the healthy range. It has decreased from 59.80 (Mar 24) to 43.37, marking a decrease of 16.43.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 25.97. This value is within the healthy range. It has decreased from 38.70 (Mar 24) to 25.97, marking a decrease of 12.73.
• For Enterprise Value (Cr.), as of Mar 25, the value is 6,487.30. It has decreased from 8,283.52 (Mar 24) to 6,487.30, marking a decrease of 1,796.22.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.23. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 6.23.
• For EV / EBITDA (X), as of Mar 25, the value is 18.46. This value exceeds the healthy maximum of 15. It has increased from 16.37 (Mar 24) to 18.46, marking an increase of 2.09.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 82.62 (Mar 24) to 0.00, marking a decrease of 82.62.
• For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has decreased from 4.86 (Mar 24) to 3.41, marking a decrease of 1.45.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness